Aclaris Therapeutics Announces Notice of Allowance for Two U.S. Patent Applications Covering Baricitnib and Decernotinib, Res...
April 04 2017 - 8:00AM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led,
biotechnology company focused on defining new standards of care in
medical and aesthetic dermatology, today announced that Columbia
University has received a Notice of Allowance from the United
States Patent and Trademark Office (USPTO) for two patent
applications covering methods related to the use and administration
of baricitinib (LY3009104) and decernotinib (VX-509), respectively,
for the treatment of hair loss disorders and for inducing hair
growth. These newly allowed patent applications are owned by The
Trustees of Columbia University in the City of New York and
exclusively licensed to Aclaris Therapeutics, Inc. These patent
applications are the latest U.S. applications to be allowed in
connection with Aclaris' janus kinase inhibitor (JAK) drug
development program for hair loss disorders. A separate
Columbia patent covering the use of ruxolitinib for the treatment
of hair loss disorders and for inducing hair growth was issued in
the U.S. in December 2015.
“We are extremely pleased with this expansion of the patent
portfolio we exclusively licensed from Columbia. These
allowances expand the breadth of and further validate our JAK
inhibitor intellectual property portfolio covering methods of use
for certain JAK inhibitors for the treatment of hair loss
disorders. The allowance of these patent applications is another
step towards the development of a robust portfolio relating to JAK
inhibition and hair loss,” said Dr. Neal Walker, President and
Chief Executive Officer of Aclaris.
The claims of these newly allowed patent applications cover
methods of inducing hair growth and treating various hair loss
disorders, including alopecia areata and androgenetic alopecia, by
administering baricitinib or decernotinib, respectively.
Additional allowed claims pertain to methods of using baricitinib
or decernotinib to treat other hair loss disorders, as well as to
treat particular phenotypes of alopecia areata.
Aclaris has exclusively licensed several patents and patent
applications involving novel selective JAK 1/3 inhibitors,
including a patent portfolio from Rigel Pharmaceuticals, Inc. that
covers ATI-50001 as well as ATI-50002, a topical formulation also
being developed as a potential treatment for alopecia areata.
In addition, Aclaris has exclusively licensed a patent portfolio
from JAKPharm and Key Organics directed to novel covalently
binding, highly selective JAK 3 inhibitors. Finally, Aclaris
has exclusively licensed a patent portfolio from Columbia
University directed to methods of using JAK inhibitors for the
treatment of alopecia areata, androgenetic alopecia, and other
dermatological conditions. This portfolio includes the
recently allowed U.S. applications discussed above, a recently
issued U.S. patent directed to methods of treating alopecia areata,
androgenetic alopecia and other hair loss disorders by
administering ruxolitinib, and a recently issued patent in Japan
directed to pharmaceutical compositions comprising ruxolitinib,
baricitinib or other JAK inhibitors for use in treating alopecia
areata, androgenetic alopecia and other hair loss disorders.
About Aclaris Therapeutics, Inc.Aclaris
Therapeutics, Inc. is a dermatologist-led biotechnology company
focused on identifying, developing and commercializing innovative
and differentiated therapies to address significant unmet needs in
medical and aesthetic dermatology. Aclaris is based in
Malvern, Pennsylvania.
Cautionary Note Regarding Forward-Looking
Statements Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words such as "believe", "expect", "may", "plan,"
"potential," "will," and similar expressions, and are based on
Aclaris' current beliefs and expectations. These forward-looking
statements include expectations regarding our JAK inhibitor
intellectual property portfolio. These statements involve
risks and uncertainties that could cause actual results to differ
materially from those reflected in such statements. Risks and
uncertainties that may cause actual results to differ materially
include uncertainties inherent in the conduct of clinical trials,
Aclaris' reliance on third parties over which it may not always
have full control, and other risks and uncertainties that are
described in the Risk Factors section of Aclaris' Annual Report on
Form 10-K for the year ended December 31, 2016 and other filings
Aclaris makes with the U.S. Securities and Exchange Commission from
time to time. These documents are available under the "Financial
Information" section of the Investors page of Aclaris' website at
http://www.aclaristx.com. Any forward-looking statements speak only
as of the date of this press release and are based on information
available to Aclaris as of the date of this release, and Aclaris
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact:
Aclaris Contact
Michael Tung, M.D.
Investor Relations
484-329-2140
mtung@aclaristx.com
Media Contact
Mariann Caprino
TogoRun
917-242-1087
M.Caprino@togorun.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2024 to May 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From May 2023 to May 2024